Tower Research Capital (TRC)’s ProShares UltraShort NASDAQ Biotechnology BIS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $23.4K | Buy |
1,325
+793
| +149% | +$14.2K | ﹤0.01% | 3364 |
|
|
2025
Q4 | $10.1K | Sell |
532
-2,010
| -79% | -$42.3K | ﹤0.01% | 3840 |
|
|
2025
Q3 | $66.5K | Buy |
2,542
+631
| +33% | +$18.8K | ﹤0.01% | 2297 |
|
|
2025
Q2 | $67.7K | Sell |
1,911
-25
| -1% | -$955 | ﹤0.01% | 2712 |
|
|
2025
Q1 | $72.2K | Sell |
1,936
-725
| -27% | -$24.8K | ﹤0.01% | 1967 |
|
|
2024
Q4 | $96.8K | Sell |
2,661
-5,055
| -66% | -$163K | ﹤0.01% | 2159 |
|
|
2024
Q3 | $232K | Buy |
7,716
+4,934
| +177% | +$149K | 0.01% | 1487 |
|
|
2024
Q2 | $92.6K | Sell |
2,782
-3,582
| -56% | -$130K | ﹤0.01% | 2633 |
|
|
2024
Q1 | $224K | Buy |
6,364
+4,003
| +170% | +$141K | 0.01% | 1342 |
|
|
2023
Q4 | $85.3K | Sell |
2,361
-2,702
| -53% | -$123K | ﹤0.01% | 2760 |
|
|
2023
Q3 | $227K | Buy |
5,063
+923
| +22% | +$38.9K | 0.01% | 1353 |
|
|
2023
Q2 | $173K | Buy |
4,140
+3,324
| +407% | +$132K | 0.01% | 1660 |
|
|
2023
Q1 | $33K | Buy |
+816
| New | +$32.5K | ﹤0.01% | 2884 |
|
|
2022
Q4 | – | Sell |
-4,062
| Closed | -$205K | – | 5897 |
|
|
2022
Q3 | $205K | Sell |
4,062
-411
| -9% | -$19.5K | ﹤0.01% | 1911 |
|
|
2022
Q2 | $241K | Sell |
4,473
-3,116
| -41% | -$174K | 0.01% | 1636 |
|
|
2022
Q1 | $366K | Sell |
7,589
-2,303
| -23% | -$118K | ﹤0.01% | 1343 |
|
|
2021
Q4 | $397K | Buy |
9,892
+1,099
| +12% | +$43K | 0.01% | 1271 |
|
|
2021
Q3 | $317K | Buy |
8,793
+6,142
| +232% | +$214K | 0.01% | 1342 |
|
|
2021
Q2 | $98K | Sell |
2,651
-743
| -22% | -$31.5K | ﹤0.01% | 2441 |
|
|
2021
Q1 | $153K | Sell |
3,394
-8,342
| -71% | -$351K | ﹤0.01% | 2229 |
|
|
2020
Q4 | $553K | Buy |
11,736
+11,685
| +22,912% | +$637K | 0.02% | 917 |
|
|
2020
Q3 | $3K | Sell |
51
-5,149
| -99% | -$329K | ﹤0.01% | 4478 |
|
|
2020
Q2 | $334K | Buy |
5,200
+3,553
| +216% | +$276K | 0.01% | 1356 |
|
|
2020
Q1 | $186K | Buy |
1,647
+1,621
| +6,235% | +$185K | 0.01% | 781 |
|
|
2019
Q4 | $3K | Sell |
26
-781
| -97% | -$100K | ﹤0.01% | 2873 |
|
|
2019
Q3 | $129K | Buy |
807
+760
| +1,617% | +$112K | 0.01% | 1201 |
|
|
2019
Q2 | $6K | Sell |
47
-4,760
| -99% | -$695K | ﹤0.01% | 2828 |
|
|
2019
Q1 | $642K | Buy |
4,807
+2,488
| +107% | +$352K | 0.04% | 464 |
|
|
2018
Q4 | $429K | Buy |
2,319
+340
| +17% | +$54.8K | 0.03% | 462 |
|
|
2018
Q3 | $247K | Sell |
1,979
-1,807
| -48% | -$243K | 0.02% | 855 |
|
|
2018
Q2 | $590K | Buy |
3,786
+260
| +7% | +$43.2K | 0.03% | 560 |
|
|
2018
Q1 | $596K | Buy |
3,526
+539
| +18% | +$86.5K | 0.05% | 388 |
|
|
2017
Q4 | $527K | Buy |
2,987
+1,065
| +55% | +$189K | 0.07% | 274 |
|
|
2017
Q3 | $317K | Sell |
1,922
-415
| -18% | -$74.8K | 0.03% | 461 |
|
|
2017
Q2 | $454K | Sell |
2,337
-3,898
| -63% | -$850K | 0.05% | 228 |
|
|
2017
Q1 | $1.39M | Buy |
6,235
+614
| +11% | +$145K | 0.14% | 60 |
|
|
2016
Q4 | $1.57M | Buy |
5,621
+4,846
| +625% | +$1.33M | 0.17% | 126 |
|
|
2016
Q3 | $196K | Sell |
775
-2,048
| -73% | -$544K | 0.02% | 496 |
|
|
2016
Q2 | $939K | Sell |
2,823
-817
| -22% | -$258K | 0.09% | 167 |
|
|
2016
Q1 | $1.27M | Buy |
3,640
+826
| +29% | +$287K | 0.19% | 90 |
|
|
2015
Q4 | $646K | Sell |
2,814
-6,596
| -70% | -$1.7M | 0.1% | 104 |
|
|
2015
Q3 | $2.9M | Buy |
9,410
+7,001
| +291% | +$1.65M | 0.28% | 48 |
|
|
2015
Q2 | $553K | Buy |
2,409
+2,404
| +48,080% | +$596K | 0.05% | 130 |
|
|
2015
Q1 | $1K | Sell |
5
-69
| -93% | -$21.1K | ﹤0.01% | 4021 |
|
|
2014
Q4 | $27K | Sell |
74
-808
| -92% | -$337K | ﹤0.01% | 1394 |
|
|
2014
Q3 | $424K | Buy |
882
+858
| +3,575% | +$457K | 0.05% | 297 |
|
|
2014
Q2 | $13K | Buy |
+24
| New | +$16.5K | ﹤0.01% | 2135 |
|
|
2014
Q1 | – | Sell |
-52
| Closed | -$43K | – | 4441 |
|
|
2013
Q4 | $43K | Buy |
+52
| New | +$50.1K | 0.01% | 1517 |
|
Other funds holding BIS
Tower Research Capital (TRC)'s BIS Position: Q1 2026 in Review
Tower Research Capital (TRC) increased its ProShares UltraShort NASDAQ Biotechnology (BIS) stake by 149% in Q1 2026, buying an estimated $14.2K and bringing the position to 1,325 shares worth $23.4K. The position accounts for ﹤0.01% of the portfolio, ranked #3364.
Tower Research Capital (TRC) first reported a position in BIS in Q4 2013 and has held it in 48 quarters since. The position peaked at $2.9M in Q3 2015. 4 funds tracked by Wall St. Rank hold BIS as of Q1 2026.
- Tower Research Capital (TRC) held 1,325 shares of ProShares UltraShort NASDAQ Biotechnology worth $23.4K as of Q1 2026.
- Tower Research Capital (TRC) bought 793 ProShares UltraShort NASDAQ Biotechnology shares in Q1 2026, an estimated $14.2K.
- ProShares UltraShort NASDAQ Biotechnology made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #3364 holding.
- Tower Research Capital (TRC) first reported a position in ProShares UltraShort NASDAQ Biotechnology in Q4 2013 and has held it in 48 quarters since.
- Tower Research Capital (TRC)'s ProShares UltraShort NASDAQ Biotechnology position peaked at $2.9M in Q3 2015.
- 4 funds tracked by Wall St. Rank held ProShares UltraShort NASDAQ Biotechnology as of Q1 2026.
Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.